- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00246402
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
Anti-Lipolytic Strategy for HIV Lipodystrophy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND:
HIV infected patients treated with HAART are at increased risk for developing significant dyslipidemia, insulin resistance, and abnormal patterns of fat distribution. While the exact mechanism responsible for these changes is not known, there is increasing evidence that patients with HIV infection and fat redistribution have increased basal rates of lipolysis and elevated circulating free fatty acids (FFA). Patients with HIV associated lipodystrophy have increased FFA levels that correlated directly with impaired glucose metabolism and triglyceride concentrations. Furthermore, acute inhibition of lipolysis in patients with HIV lipodystrophy and insulin resistance results in improvement in insulin sensitivity. However, long-term administration of lipolytic blocking agents has not been evaluated in this patient population. Acipimox, a nicotinic acid analogue and a potent inhibitor of lipolysis, is an established therapy for dyslipidemia. In addition, through effects on lowering circulating FFA, acute administration of acipimox has been shown to improve insulin sensitivity in other populations, including lean and obese individuals and patients with type II diabetes. This study will test the hypothesis that chronic administration of acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing HAART associated metabolic disturbances.
DESIGN NARRATIVE:
The study will be a 3-month double-blind placebo-controlled trial of 250 mg of acipimox three times daily in 30 patients with HAART lipodystrophy. The primary clinical endpoint of this study will be the change in fasting triglyceride concentration, comparing baseline values to those obtained after 3 months of acipimox or placebo. Insulin sensitivity, an important secondary endpoint, will be determined by hyperinsulinemic euglycemic clamp studies. Rates of lipolysis in the fasting state will be quantified by a 3-hour infusion of stable isotope-labeled glycerol. Indirect calorimetry will be used to assess changes in resting energy expenditure. Cross-sectional computed tomography (CT) imaging of the thigh and abdomen will allow for measurement of visceral and subcutaneous fat areas. Dual energy x-ray absorptiometry (DEXA) will be used to determine whole body fat mass.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented HIV infection
- Stable antiretroviral regimen for greater than 3 months
- Hypertriglyceridemia (fasting triglycerides greater than 150mg/dl)
- Evidence of fat redistribution (e.g., increased abdominal or cervical fat, and/or decreased subcutaneous fat of the face, arms, or legs) on physical exam
Exclusion Criteria:
- Current therapy with a lipid lowering medication (e.g., fibrates, HMG CoA reductase inhibitors, resins) or treatment with these agents in the 3 months prior to study entry
- Current use of hormone replacement therapy, oral contraceptives for women, or supraphysiologic testosterone therapy in men
- Fasting triglycerides greater than 1000mg/dl
- Active alcohol or substance abuse
- Active peptic ulcer disease
- History of renal failure or serum creatinine greater than 2.0
- Serious opportunistic infection within the 3 months prior to study entry
- Hemoglobin less than 11.0 mg/dl
- Elevated transaminase levels (AST or ALT greater than 2.5x the upper limit of normal)
- Previously diagnosed diabetes mellitus or patients receiving current treatment for diabetes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Fasting Triglyceride Concentration (Initial, after 3 months)
|
Secondary Outcome Measures
Outcome Measure |
---|
Insulin Sensitivity (Initial, after 3 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Colleen M. Hadigan, MD, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Hyperinsulinism
- Lipid Metabolism Disorders
- Dyslipidemias
- Heart Diseases
- Cardiovascular Diseases
- Insulin Resistance
- Hyperlipidemias
- Hypertriglyceridemia
- Hyperlipoproteinemias
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Acipimox
Other Study ID Numbers
- 337
- R21HL073675 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Nantes University HospitalDirectorate of Health Care SupplyNot yet recruitingHeart Diseases | Heart Failure | Heart Valve Diseases
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
Shanghai Zhongshan HospitalCompletedElectrocardiogram, Valvular Heart DiseaseChina, United Kingdom
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
Clinical Trials on Acipimox
-
University of AarhusCompletedHeart FailureDenmark
-
Brigham and Women's HospitalCompletedMetabolic SyndromeUnited States
-
University of AarhusTerminated
-
Maastricht University Medical CenterRecruiting
-
Medical University of ViennaCompleted
-
Brigham and Women's HospitalCompletedType 2 Diabetes MellitusUnited States
-
Charles University, Czech RepublicEnrolling by invitationBulimia Nervosa | Eating Disorder
-
University of AarhusCompletedObesity | DiabetesDenmark
-
Liverpool John Moores UniversityLiverpool University Hospitals NHS Foundation Trust; Royal Liverpool University... and other collaboratorsCompleted
-
University of Colorado, DenverPfizer; US Department of Veterans AffairsCompletedType 2 DiabetesUnited States